622 related articles for article (PubMed ID: 30565239)
21. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.
Paterson AM; Lovitch SB; Sage PT; Juneja VR; Lee Y; Trombley JD; Arancibia-Cárcamo CV; Sobel RA; Rudensky AY; Kuchroo VK; Freeman GJ; Sharpe AH
J Exp Med; 2015 Sep; 212(10):1603-21. PubMed ID: 26371185
[TBL] [Abstract][Full Text] [Related]
22. CTLA4 gene variants in autoimmunity and cancer: a comparative review.
Ghaderi A
Iran J Immunol; 2011 Sep; 8(3):127-49. PubMed ID: 21931200
[TBL] [Abstract][Full Text] [Related]
23. A Patient with CTLA-4 Haploinsufficiency with Multiple Autoimmune Presentations: A Case Report.
Zaremehrjardi F; Baniadam L; Seif F; Arshi S; Bemanian MH; Shokri S; Rezaeifar A; Fallahpour M; Nabavi M
Iran J Immunol; 2020 Sep; 17(3):244-249. PubMed ID: 32996901
[TBL] [Abstract][Full Text] [Related]
24. Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy.
Kim GR; Choi JM
Mol Cells; 2022 Aug; 45(8):513-521. PubMed ID: 35950451
[TBL] [Abstract][Full Text] [Related]
25. Regulatory T cells control epitope spreading in autoimmune arthritis independent of cytotoxic T-lymphocyte antigen-4.
Yang M; Klocke K; Hernandez CM; Xu B; Gjertsson I; Wing K; Holmdahl R
Immunology; 2018 Dec; 155(4):446-457. PubMed ID: 29992549
[TBL] [Abstract][Full Text] [Related]
26. Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency.
Cepika AM; Sato Y; Liu JM; Uyeda MJ; Bacchetta R; Roncarolo MG
J Allergy Clin Immunol; 2018 Dec; 142(6):1679-1695. PubMed ID: 30527062
[TBL] [Abstract][Full Text] [Related]
27. Measuring CTLA-4-Dependent Suppressive Function in Regulatory T Cells.
Hou TZ; Qureshi OS; Sansom DM
Methods Mol Biol; 2019; 1899():87-101. PubMed ID: 30649767
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.
Stumpf M; Zhou X; Chikuma S; Bluestone JA
Eur J Immunol; 2014 Jun; 44(6):1737-46. PubMed ID: 24648182
[TBL] [Abstract][Full Text] [Related]
29. CTLA-4 expressed by FOXP3
Klocke K; Holmdahl R; Wing K
Immunology; 2017 Sep; 152(1):125-137. PubMed ID: 28497863
[TBL] [Abstract][Full Text] [Related]
30. CTLA-4: From mechanism to autoimmune therapy.
Hosseini A; Gharibi T; Marofi F; Babaloo Z; Baradaran B
Int Immunopharmacol; 2020 Mar; 80():106221. PubMed ID: 32007707
[TBL] [Abstract][Full Text] [Related]
31. Current understanding of CTLA-4: from mechanism to autoimmune diseases.
Hossen MM; Ma Y; Yin Z; Xia Y; Du J; Huang JY; Huang JJ; Zou L; Ye Z; Huang Z
Front Immunol; 2023; 14():1198365. PubMed ID: 37497212
[TBL] [Abstract][Full Text] [Related]
32. CTLA-4 (CD152) blockade does not cause a pro-inflammatory cytokine profile in regulatory T cells.
Kolar P; Hoff H; Maschmeyer P; Burmester GR; Brunner-Weinzierl MC
Clin Exp Rheumatol; 2011; 29(2):254-60. PubMed ID: 21418778
[TBL] [Abstract][Full Text] [Related]
33. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop.
Marangoni F; Zhakyp A; Corsini M; Geels SN; Carrizosa E; Thelen M; Mani V; Prüßmann JN; Warner RD; Ozga AJ; Di Pilato M; Othy S; Mempel TR
Cell; 2021 Jul; 184(15):3998-4015.e19. PubMed ID: 34157302
[TBL] [Abstract][Full Text] [Related]
34. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
[TBL] [Abstract][Full Text] [Related]
35. CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity.
Vogel I; Kasran A; Cremer J; Kim YJ; Boon L; Van Gool SW; Ceuppens JL
Eur J Immunol; 2015 Jun; 45(6):1832-41. PubMed ID: 25727069
[TBL] [Abstract][Full Text] [Related]
36. CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells.
Ovcinnikovs V; Ross EM; Petersone L; Edner NM; Heuts F; Ntavli E; Kogimtzis A; Kennedy A; Wang CJ; Bennett CL; Sansom DM; Walker LSK
Sci Immunol; 2019 May; 4(35):. PubMed ID: 31152091
[TBL] [Abstract][Full Text] [Related]
37. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
38. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.
Togashi Y; Shitara K; Nishikawa H
Nat Rev Clin Oncol; 2019 Jun; 16(6):356-371. PubMed ID: 30705439
[TBL] [Abstract][Full Text] [Related]
39. Do common infections trigger disease-onset or -severity in CTLA-4 insufficiency?
Krausz M; Mitsuiki N; Falcone V; Komp J; Posadas-Cantera S; Lorenz HM; Litzman J; Wolff D; Kanariou M; Heinkele A; Speckmann C; Häcker G; Hengel H; Gámez-Díaz L; Grimbacher B
Front Immunol; 2022; 13():1011646. PubMed ID: 36405723
[TBL] [Abstract][Full Text] [Related]
40. Role of
Kailashiya V; Sharma HB; Kailashiya J
J Clin Pathol; 2019 Oct; 72(10):659-662. PubMed ID: 31340988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
